Investing.com - BioXcel Therapeutics reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
BioXcel Therapeutics announced earnings per share of $-1.49 on revenue of $140K. Analysts polled by Investing.com anticipated EPS of $-1.32 on revenue of $1.12M.
BioXcel Therapeutics shares are down 23.1% from the beginning of the year and are trading at $11.41 , down-from-52-week-high.
BioXcel Therapeutics follows other major Healthcare sector earnings this month
BioXcel Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar